PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients

NCT00948090 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborators

[object Object]